Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
Cancer Discov. 2012 Sep;2(9):812-25. doi: 10.1158/2159-8290.CD-12-0116. Epub 2012 Jun 29.
Understanding factors required for DNA replication will enrich our knowledge of this important process and potentially identify vulnerabilities that can be exploited in cancer therapy. We applied an assay that measures the stability of maintenance of an episomal plasmid in human tissue culture cells to screen for new DNA replication factors. We identify an important role for DDX5 in G(1)-S-phase progression where it directly regulates DNA replication factor expression by promoting the recruitment of RNA polymerase II to E2F-regulated gene promoters. We find that the DDX5 locus is frequently amplified in breast cancer and that breast cancer-derived cells with amplification of DDX5 are much more sensitive to its depletion than breast cancer cells and a breast epithelial cell line that lacks DDX5 amplification. Our results show a novel role for DDX5 in cancer cell proliferation and suggest DDX5 as a therapeutic target in breast cancer treatment.
DDX5 is required for cell proliferation by controlling the transcription of genes expressing DNA replication proteins in cancer cells in which the DDX5 locus is amplified, and this has uncovered a dependence on DDX5 for cell proliferation. Given the high frequency of DDX5 amplification in breast cancer, our results highlight DDX5 as a promising candidate for targeted therapy of breast tumors with DDX5 amplification, and indeed we show that DDX5 inhibition sensitizes a subset of breast cancer cells to trastuzumab.
了解 DNA 复制所需的因素将丰富我们对这一重要过程的认识,并有可能发现可在癌症治疗中利用的脆弱性。我们应用了一种测量人组织培养细胞中维持附加质粒稳定性的测定法,以筛选新的 DNA 复制因子。我们发现 DDX5 在 G1-S 期进展中起着重要作用,它通过促进 RNA 聚合酶 II 向 E2F 调节基因启动子的募集,直接调节 DNA 复制因子的表达。我们发现 DDX5 基因座在乳腺癌中经常扩增,并且乳腺癌衍生的扩增了 DDX5 的细胞比乳腺癌细胞和缺乏 DDX5 扩增的乳腺上皮细胞系对其缺失更为敏感。我们的结果表明 DDX5 在癌细胞增殖中的新作用,并表明 DDX5 是乳腺癌治疗中的一个有希望的治疗靶点。
DDX5 通过控制扩增的 DDX5 基因座中表达 DNA 复制蛋白的基因的转录来控制癌细胞的增殖,这揭示了癌细胞增殖对 DDX5 的依赖性。鉴于 DDX5 在乳腺癌中的高扩增频率,我们的结果突出了 DDX5 作为针对具有 DDX5 扩增的乳腺肿瘤的靶向治疗的有前途的候选物,事实上,我们表明 DDX5 抑制使一部分乳腺癌细胞对曲妥珠单抗敏感。